As such, a larger proportion of patients are more likely to be on appropriate DM therapy, which typically includes metformin as a front line agent, and may abrogate the potential adverse effect of insulin resistance or IGF-1 on survival and account for our improved survival findings. This evidence concerns the gene IGF1 and diabetes mellitus.